Fosun Pharmaceutical’s $135 Million COVID-19 Vaccine Strategic Alliance with Biopharmaceutical New Technologies

Michael Patrini

Paul Hastings LLP advised Shanghai Fosun Pharmaceutical (Group) Co., Ltd in its alliance with Biopharmaceutical New Technologies of Germany. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SH,…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Michael Patrini

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here